| AED | antiepileptic drug; antihidrotic ectodermal dysplasia; automatic external defibrillator |
|---|---|
| AHD | acquired hepatocerebral degeneration; acute heart disease; antihyaluronidase; antihypertensive drug;... |
| AL | absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru... |
| AMA-DE | American Medical Association Drug Evaluation |
| AMSAODD | American Medical Society on Alcoholism and Other Drug Dependencies |
| orphan drug | A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential. (09 Oct 1997) |
|---|---|
| orphan drug act | Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug. (14 Nov 1997) |
| orphan drug production | Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others. (12 Dec 1998) |
| targeted drug delivery | Delivering a drug to a specific site in the body where it has the greatest effect, instead of allowing it to diffuse to various sites, where it may cause damage or trigger side effects. (14 Nov 1997) |
| united states food and drug administration | An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. (12 Dec 1998) |
| fixed drug eruption | A type of drug eruption that recurs at a fixed site (or sites) following the administration of a particular drug; the lesions usually consist of intensely erythematous and purplish, sharply demarcated macules, and occasionally of herpetic vesicles; the affected areas undergo gradual involution, but flare and enlarge on readministration of the offending drug and may become hyperpigmented. Iodine eruption, an acneform or follicular eruption or granulomatous lesion caused by a reaction to systemic iodine or iodide administration. Kaposi's varicelliform eruption, a now rare complication of vaccinia superimposed on atopic dermatitis, with generalised vesicles and vesicopapules and high fever. Synonym: eczema vaccinatum. (05 Mar 2000) |
| food and drug administration | The U.S. Agency responsible for regulation of biotechnology foodproducts. The major laws under which the agency has regulatory powersinclude the Food, Drug, and Cosmetic act, and the Public Health Service Act. (09 Oct 1997) |
| food-drug interactions | The pharmacological result, either desirable or undesirable, of drugs interacting with components of the diet. (12 Dec 1998) |
| legislation, drug | Laws concerned with manufacturing, dispensing, and marketing of drugs. (12 Dec 1998) |
| acupuncture therapy | Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. Heat or moxibustion and acupressure may be used in conjunction. (12 Dec 1998) |
| adjuvant therapy | <oncology, pharmacology> Treatment that is added to increase the effectiveness of a primary treatment. In cancer, adjuvant treatment usually refers to chemotherapy, hormonal therapy or radiation therapy after surgery to increase the likelihood of killing all cancer cells. (14 May 1997) |
| alternative therapy | A term given to nonconventional therapy usually given by persons who do not have a medical qualification. (16 Dec 1997) |
| analytic therapy | Short term for psychoanalytic therapy. (05 Mar 2000) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| anticoagulant therapy | The use of anticoagulant drugs to reduce or prevent intravascular or intracardiac clotting. (05 Mar 2000) |